Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
4.740
+0.140 (3.04%)
At close: Nov 6, 2026, 4:00 PM EST
4.920
+0.180 (3.80%)
After-hours: Nov 6, 2026, 7:59 PM EST
TNXP Revenue
Tonix Pharmaceuticals Holding had revenue of $13.54M in the quarter ending June 30, 2026, with 577.88% growth. This brings the company's total for the last twelve months to $29.10M, up 196.02% year-over-year. In the year 2025, Tonix Pharmaceuticals Holding had annual revenue of $13.11M with 29.85% growth. That makes Tonix Pharmaceuticals Holding the 31,573rd largest company in the world by revenue and 4,166th in the United States.
Revenue (ttm)
$29.10M
Revenue Growth
+196.02%
P/S Ratio
2.79
Revenue / Employee
$204,944
Employees
142
Market Cap
81.30M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.11M | 3.01M | 29.85% |
| Dec 31, 2024 | 10.09M | 2.33M | 29.94% |
| Dec 31, 2023 | 7.77M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 63.82M |
| Atara Biotherapeutics | 6.19M |
| NeurAxis | 5.32M |
| Rani Therapeutics Holdings | 4.88M |
| Rallybio | 434.00K |
| NeOnc Technologies Holdings | 39.99K |
| Genelux | 8.00K |
TNXP News
- 4 days ago - Tonix Pharmaceuticals to Present at Guggenheim's 3rd Annual Healthcare Innovation Conference - GlobeNewsWire
- 6 days ago - Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation - GlobeNewsWire
- 12 days ago - Tonix Pharmaceuticals presents data from RELIEF, RESILIENT studies of Tonmya - TheFly
- 12 days ago - Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain - GlobeNewsWire
- 13 days ago - Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026 - GlobeNewsWire
- 13 days ago - Tonix Pharmaceuticals initiated with a Buy at Canaccord - TheFly
- 19 days ago - Tonix Pharmaceuticals price target lowered to $26 from $27 at Raymond James - TheFly
- 20 days ago - Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain - GlobeNewsWire